Literature DB >> 22644512

Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis.

Ju Hyun Shim1, Da-Lim Yoon, Seungbong Han, Young-Joo Lee, Sung-Gyu Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee.   

Abstract

BACKGROUND: Serum alpha-fetoprotein (AFP) is frequently used to predict posthepatectomy outcomes in patients with hepatocellular carcinoma (HCC), but its predictive value is still not established. Therefore, we assessed the prognostic significance of AFP status.
METHODS: Of 525 patients undergoing curative hepatectomy for HCC, 290 had preoperative AFP levels of ≥20 ng/mL (AFP-positive group) and 235 had AFP levels of <20 ng/mL (AFP-negative group). We compared the 2 groups with respect to time-to-recurrence, using the inverse probability of treatment weighted (IPTW) for the entire cohort and propensity score matching, and the cumulative incidence of HCC-specific mortality using competing risks regression.
RESULTS: During follow-up (median duration 64 months, range 2-137 months), HCC recurred in 54.9 % of the AFP-negative group and 52.4 % of the AFP-positive group; there was no death without recurrence. After IPTW adjustment, time-to-recurrence did not differ in the 2 groups (hazard ratio [HR] 0.86, 95 % confidence interval [95 % CI] 0.66-1.12; P = 0.28). In a propensity-score matched cohort (152 pairs), time-to-recurrence data were similar to those obtained by IPTW adjustment (HR 0.91, 95 % CI 0.65-1.25; P = 0.55). There was no difference in recurrence pattern (site and stage) or treatment between the 2 groups even after propensity-score matching. The adjusted HR evaluating the impact of AFP positivity on the risk of HCC-specific mortality was 0.77 (95 % CI 0.54-1.08; P = 0.13) A multivariable competing risks analysis also failed to reveal a significant correlation between baseline AFP level and HCC-specific mortality in the AFP-positive group.
CONCLUSIONS: Preoperative AFP levels are not useful for predicting recurrence or survival endpoints following curative hepatectomy for HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644512     DOI: 10.1245/s10434-012-2416-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  26 in total

1.  Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis.

Authors:  Xin-Sen Xu; Yong Wan; Si-Dong Song; Wei Chen; Run-Chen Miao; Yan-Yan Zhou; Ling-Qiang Zhang; Kai Qu; Si-Nan Liu; Yue-Lang Zhang; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: A case report.

Authors:  Rongxing Zhou; Minjia Zhang; Nansheng Cheng; Yong Zhou
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

3.  Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date?

Authors:  Fabrice Muscari; Charlotte Maulat
Journal:  Transl Gastroenterol Hepatol       Date:  2020-10-05

4.  Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

Authors:  Vaneet Jearth; Prachi S Patil; Shaesta Mehta; Sridhar Sundaram; Vishal Seth; Mahesh Goel; Shraddha Patkar; Munita Bal; Vidya Rao
Journal:  J Clin Exp Hepatol       Date:  2021-11-16

5.  Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.

Authors:  Fei Yin; Xin Han; Shu-Kun Yao; Xiao-Ling Wang; Hui-Chai Yang
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

6.  Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma.

Authors:  N Imai; A Kinoshita; H Onoda; A Iwaku; M Oishi; K Tanaka; N Fushiya; K Koike; H Nishino; H Tajiri
Journal:  Clin Transl Oncol       Date:  2012-12-21       Impact factor: 3.405

7.  Prognostic value of preoperative alpha-fetoprotein (AFP) level in patients receiving curative hepatectomy- an analysis of 1,182 patients in Hong Kong.

Authors:  Miu Yee Chan; Wong Hoi She; Wing Chiu Dai; Simon Hing Yin Tsang; Kenneth Siu Ho Chok; Albert Chi Yan Chan; Jame Fung; Chung Mau Lo; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2019-07-11

8.  High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy.

Authors:  Qiujin Shen; Xin-Rong Yang; Yexiong Tan; Haiyan You; Yang Xu; Wei Chu; Tianxiang Ge; Jian Zhou; Shuang-Jian Qiu; Ying-Hong Shi; Zhigang Zhang; Jianren Gu; Hongyang Wang; Jia Fan; Wenxin Qin
Journal:  Hepat Oncol       Date:  2015-04-01

9.  Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Authors:  Christine C Hsu; Abhishek Goyal; Alina Iuga; Saravanan Krishnamoorthy; Valerie Lee; Elizabeth C Verna; Shuang Wang; Fei-Na Chen; Rosa Rodriguez; Jean Emond; Paul Berk; Jay Lefkowitch; Lorna Dove; Robert S Brown; Abby B Siegel
Journal:  Clin Transl Gastroenterol       Date:  2015-02-05       Impact factor: 4.488

10.  Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.

Authors:  Jian-Hong Zhong; Bang-De Xiang; Wen-Feng Gong; Yang Ke; Qin-Guo Mo; Liang Ma; Xing Liu; Le-Qun Li
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.